Not exact matches
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept, used to treat vision loss from diabetic
macular edema (DME), and approximately 20 to 30 times more expensive than bevacizumab, are
not cost - effective for treatment of DME compared to bevacizumab unless their prices decrease substantially, according to a study published online by JAMA Ophthalmology.
You may have temporary vision loss after laser treatment Diabetic retinopathy does
not require treatment in its early stages unless the person has
macular edema.
Long - term complications, especially if diabetes isn't properly treated, can result, including cardiovascular disease, heart attack, eye disease, vision loss,
macular edema, kidney disease, and neuropathy.